This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to undertake an introductory report, on the cost-effectiveness of aortic valve replacement (AVR), using a large database with long-term follow-up data.
Interventions
AVR was compared with a strategy of maintaining patients with heart valve disease without surgery.
Location/setting
USA/hospital.
Methods

Analytical approach:
This economic evaluation was based on a statistical simulation model, with a lifetime horizon. The authors did not explicitly state the perspective adopted.
Effectiveness data:
The clinical data on AVR were derived from a database of 4,617 patients aged 20 years or older who underwent AVR at three hospitals in Portland (Oregon) from 1961 to 2003. All patients were followed-up over their lifetime using a combination of annual mailed questionnaires and telephone interviews. The data for those patients who were still alive at the time of this study were considered to be censored and the expected survival was simulated using a Gompertz parametric regression model. The survival of patients without surgery for heart valve disease was derived from: a systematic review of the literature in English in the MEDLINE database, the American College of Cardiology and the American Heart Association guidelines, and a published study. The inclusion criteria and details of the statistical tests used to derive the survival data were reported. The key clinical endpoint was survival for both groups of patients.
Monetary benefit and utility valuations:
The utility valuations were estimated by mapping quality of life scores to New York Heart Association (NYHA) classes derived from the hospital database.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure.
Cost data:
The economic analysis assumed that the lifetime cost of maintaining patients with heart valve disease without surgery was zero. There were three major categories of costs associated with AVR: primary surgery, ongoing maintenance
